What HCT Regenerative does

HCT Regenerative Co., Ltd. is a privately held Taiwanese tissue processing company founded in 2016 and headquartered in New Taipei City (Tamsui District). It is the first company in Taiwan to specialize in processing human tissue into orthobiologics and regenerative biomaterials for clinical use, and is the first and only establishment in Taiwan accredited by the American Association of Tissue Banks (AATB), in addition to holding a TFDA license for human cellular and tissue-based products (HCT/Ps). The company operates a Class 10,000 cleanroom using aseptic technique and runs comprehensive donor screening including Anti-HIV-1/2, HIV-1 NAT, HBsAg, HBV NAT, Anti-HBc, Anti-HBs, Anti-HCV, HCV NAT, RPR, and TPPA testing.

Name

HCT Regenerative

Legal name

HCT Regenerative Co., Ltd.

Website

https://hctregenerative.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

HCT Regenerative Co., Ltd. is a Taiwan-based (New Taipei City) tissue processing company, founded 2016, that manufactures human allograft orthobiologics and regenerative biomaterials — including amniotic membrane, bone particulate, spinal spacer, and sports tissue products — for hospitals and medical institutions.

Ownership category

akta.pro rank

Product category

Orthobiologics and Regenerative Biomaterials

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Tissue processing
• Orthobiologics products
• Regenerative biomaterials
• Allograft manufacturing
• Human tissue products

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Others

Revenue model

1. Human Tissue and Orthobiologics Products: Sale of processed human cellular and tissue-based products (HCT/Ps) including amniotic membranes, bone allografts, spinal spacers, and sports tissue allografts for clinical use in regenerative medicine applications

Distribution channels1 record

Core offering

HCT Regenerative processes donated human tissue into a portfolio of human cellular and tissue-based products (HCT/Ps) — amniotic membrane allografts, spinal allograft spacers, bone particulate allografts, and musculoskeletal tendon allografts — sold to hospitals, clinics, and medical institutions for wound care, orthopedic surgery, spinal fusion, and sports medicine applications. Manufacturing is performed in a Class 10,000 cleanroom under TFDA licensing and AATB accreditation, with rigorous donor screening and aseptic processing.

Product overview

HCT Regenerative is the first company in Taiwan to specialize in tissue processing, utilizing human tissue to create orthobiologics and regenerative biomaterials for clinical use. The company's product portfolio consists of five main allograft product lines: AMNIOGEN® and AMNIOAID® amniotic membrane allografts for wound care and tissue regeneration applications; LIFEGRAFT® precision spinal allograft spacers for spinal fusion procedures; OSTEOAID® bone particulate allografts in various formulations for bone regeneration; and Sports Tissue allografts including tendon products for sports medicine. All products are human cellular and tissue-based products (HCT/Ps) regulated under TFDA licensing and AATB accreditation.

Differentiator

Problem solved

Functional benefit

Brands

• AMNIOGEN®: Amniotic Membrane Allograft product line for clinical use
• AMNIOAID®
• LIFEGRAFT®
• OSTEOAID®
• Sports Tissue

Products and services

• AMNIOGEN® Amniotic Membrane Allograft

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• CGBIOcoreChannel Partner/ Reseller/ Distributor · 7 April 2026HCT Regenerative signed an exclusive supply agreement with CGBIO for distribution of CGDerm One-Step in Taiwan. This partnership was part of CGBIO's KIMES 2026 exhibition in Seoul, where CGBIO showcased its comprehensive medical device portfolio spanning aesthetic, wound care, bone and spine, and surgical fields. The agreement represents HCT Regenerative's role as a supply partner enabling CGBIO's market access in Taiwan.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• MTF Biologics: US-based nonprofit tissue bank and one of the largest processors of musculoskeletal allografts, sports tissue, and amniotic membrane products. Directly comparable as a multi-product allograft tissue bank serving orthopedic, spine, sports medicine, and wound care markets.
• Organogenesis: Public regenerative medicine company focused on wound care and surgical biologics including amniotic membrane products (e.g., Apligraf, Affinity, NuShield). Comparable in wound-care regenerative tissue offerings and clinical sales model.
• LifeNet Health: Nonprofit tissue bank specializing in musculoskeletal allografts, dermal matrices, and cardiac valves with AATB accreditation. Directly comparable as an AATB-accredited tissue processor offering bone, tendon, and sports medicine allografts to orthopedic customers.
• MiMedx Group: Publicly traded developer of regenerative wound care and orthobiologics products using placental tissue (amniotic membrane). Comparable in amniotic membrane allograft product line and wound care/surgical tissue focus.
• Tides Medical: Specialty wound care company distributing amniotic membrane allografts (e.g., AmnioBind, Artacent) for chronic and acute wounds. Directly comparable in AMNIOGEN/AMNIOAID-style amniotic membrane wound care products.
• Vivex Biologics: Specialty orthobiologics company marketing amniotic, umbilical, and bone grafting products for spine, orthopedic, and wound care. Comparable as a focused orthobiologics allograft processor.
• AlloSource: AATB-accredited nonprofit tissue bank producing allografts for sports medicine, spine, orthopedics, and wound care. Highly comparable in product mix (bone, tendon, amniotic) and regulatory positioning.

Broad incumbents

• Integra LifeSciences: Large public medical device company with an orthobiologics and regenerative tissue portfolio (including DERMAMATRIX, SurgiMend). Comparable as a broad incumbent offering overlapping wound care, bone, and tissue regeneration products through a wider portfolio.
• Geistlich Pharma: Swiss-based regenerative medicine company specializing in bone and tissue regeneration products (e.g., Bio-Oss, Bio-Gide) used in dental and orthopedic surgery. Comparable as a broad incumbent in bone graft substitutes and orthobiologics.

Emerging players

• SurGenTec: Emerging orthobiologics developer focused on bone graft substitutes and regenerative spine/orthopedic products. Comparable as a niche emerging player in the bone graft substitute category overlapping with HCT's OSTEOAID and LIFEGRAFT lines.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HCT Regenerative